drugset / Trial / NCT05623345
Psoriatic Arthritis Study of Izokibep
RandomizedParallel-groupDouble-blindTreatment
Summary
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
Timeline
- Start
- 2022-11-21
- Primary completion
- 2023-11-30
- Completion
- 2024-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | — | Subcutaneous |